written on 30.05.2014

ASCO tackles a tough question: When is a cancer drug too pricey?


ASCO wants to provide oncologists with a scorecard they can use to determine when the benefits of a drug don't justify its cost. The first hints of how that scorecard is shaping up will be revealed starting today, at the annual ASCO conference in Chicago